Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Arthur P. Decillis"'
Autor:
Jessica Baker Flechtner, Thomas A. Davis, Pamela M. Carroll, Charles G. Drake, Kwok-Kin Wong, Elizabeth M. Jaffee, Parul Agnihotri, Wendy Broom, Daniel B. DeOliveira, Kyle Ferber, Emily Tjon, Vijetha Vemulapalli, James J. Foti, Arthur P. DeCillis, Ulka N. Vaishampayan, Mark N. Stein, Maura L. Gillison, Melissa L. Johnson, Przemyslaw Twardowski, Roger B. Cohen, Victoria L. DeVault, Hanna Starobinets, Lisa K. McNeil, Hubert Lam
Neoantigens are critical targets of antitumor T-cell responses. The ATLAS bioassay was developed to identify neoantigens empirically by expressing each unique patient-specific tumor mutation individually in Escherichia coli, pulsing autologous dendri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69391e7bebbc1a1098be422e085f1940
https://doi.org/10.1158/2159-8290.c.6548228.v1
https://doi.org/10.1158/2159-8290.c.6548228.v1
Autor:
Jessica Baker Flechtner, Thomas A. Davis, Pamela M. Carroll, Charles G. Drake, Kwok-Kin Wong, Elizabeth M. Jaffee, Parul Agnihotri, Wendy Broom, Daniel B. DeOliveira, Kyle Ferber, Emily Tjon, Vijetha Vemulapalli, James J. Foti, Arthur P. DeCillis, Ulka N. Vaishampayan, Mark N. Stein, Maura L. Gillison, Melissa L. Johnson, Przemyslaw Twardowski, Roger B. Cohen, Victoria L. DeVault, Hanna Starobinets, Lisa K. McNeil, Hubert Lam
Supplementary Table from An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::078f1d611a139d47d9a2839b5a415c3e
https://doi.org/10.1158/2159-8290.22536755
https://doi.org/10.1158/2159-8290.22536755
Autor:
Jessica Baker Flechtner, Thomas A. Davis, Pamela M. Carroll, Charles G. Drake, Kwok-Kin Wong, Elizabeth M. Jaffee, Parul Agnihotri, Wendy Broom, Daniel B. DeOliveira, Kyle Ferber, Emily Tjon, Vijetha Vemulapalli, James J. Foti, Arthur P. DeCillis, Ulka N. Vaishampayan, Mark N. Stein, Maura L. Gillison, Melissa L. Johnson, Przemyslaw Twardowski, Roger B. Cohen, Victoria L. DeVault, Hanna Starobinets, Lisa K. McNeil, Hubert Lam
Supplementary Figure from An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d1af50888ce099e83501cd69eefc22b
https://doi.org/10.1158/2159-8290.22536761.v1
https://doi.org/10.1158/2159-8290.22536761.v1
Autor:
Wendy Broom, Elizabeth M. Jaffee, Daniel DeOliveira, Victoria L. DeVault, Charles G. Drake, Ulka N. Vaishampayan, Arthur P. Decillis, Vijetha Vemulapalli, Maura L. Gillison, Mark N. Stein, Pamela M. Carroll, Kyle Ferber, Parul Agnihotri, Emily Tjon, Hubert Lam, Jessica Flechtner, James Foti, Roger B. Cohen, Lisa K. McNeil, Hanna Starobinets, Melissa Lynne Johnson, Przemyslaw Twardowski, Thomas A. Davis, Kwok-Kin Wong
Publikováno v:
Cancer Discovery. 11:696-713
Neoantigens are critical targets of antitumor T-cell responses. The ATLAS bioassay was developed to identify neoantigens empirically by expressing each unique patient-specific tumor mutation individually in Escherichia coli, pulsing autologous dendri
Autor:
Anthony Tolcher, Joseph Paul Eder, David Sommerhalder, Sophia Gayle, Paul Pearson, Deb Chapman, Arthur P. DeCillis, Anish Thomas, Funda Meric-Bernstam
Publikováno v:
Molecular Cancer Therapeutics. 20:P047-P047
Background Tumor-targeted drug delivery technologies are urgently needed to overcome the lack of tumor selectivity, a major drawback of conventional chemotherapy. In addition, the acidic intercellular microenvironment in solid tumors traps weak acid/
Autor:
C. Michel Zwaan, Todd M. Cooper, Arthur P DeCillis, Jingdong Xie, Pamela Downs, Michele Vigliotti, Cara A Rabik, Edward A. Kolb, Derek E. Mires
Publikováno v:
Blood. 134:3937-3937
Background Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations occur in 10%-15% of pediatric/adolescent patients with AML and are associated with treatment resistance, risk of relapse, and poor survival. Nearly 50% of children
Autor:
Moshe Talpaz, Hagop M. Kantarjian, Fei Huang, M. Anne Blackwood-Chirchir, Jorge E. Cortes, Charles L. Sawyers, Claude Nicaise, Eric Bleickardt, Arthur P. DeCillis, Neil P. Shah, Susan O'Brien, Tai-Tsang Chen, John Nicoll, Nicholas J. Donato, Ron Paquette, Vishwanath Iyer
Publikováno v:
The New England journal of medicine. 354(24)
Background The BCR-ABL tyrosine kinase inhibitor imatinib is effective in Philadelphia chromosome–positive (Ph-positive) leukemias, but relapse occurs, mainly as a result of the outgrowth of leukemic subclones with imatinib-resistant BCR-ABL mutati
Autor:
Quincy Siu-Chung Chu, Louis Denis, Stephen P. Letrent, Kathleen Molpus, Arthur P. DeCillis, Leonel Ochoa, Eric K. Rowinsky, Sun Young Rha, Garry Schwartz, Bharat Damle, Lisa A. Hammond, Brian Roedig
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 10(15)
Purpose: The oral fluoropyrimidine S-1, which consists of a mixture of a 5-fluorouracil (5-FU) prodrug (tegafur), a dihydropyrimidine dehydrogenase inhibitor [5-chloro-2,4-dihydroxypyrimidine (CDHP)], and an inhibitor of orotate phosphoribosyltransfe
Autor:
Steven J, Cohen, Cynthia G, Leichman, Gwen, Yeslow, Mary, Beard, April, Proefrock, Brian, Roedig, Bharat, Damle, Stephen P, Letrent, Arthur P, DeCillis, Neal J, Meropol
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 8(7)
To determine the maximum tolerated dose, dose-limiting toxicities(DLTs), and pharmacokinetics of S-1, a combination of tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP), and oxonic acid, administered once daily in patients with advanced cancer.Eighteen
Autor:
Arthur P. DeCillis, Charles L. Sawyers, Fei Huang, John Nicoll, Neil P. Shah, Edwin A. Clark, Hagop M. Kantarjian, Moshe Talpaz, Stephen A. Bai, Nicholas J. Donato
Publikováno v:
Blood. 104:1-1
Disease relapse in CML patients treated with imatinib is often associated with mutations in the BCR-ABL gene that interfere with the ability of imatinib to block BCR-ABL kinase activity. BMS-354825 is a novel, orally available, dual SRC/ABL kinase in